COME SEE US IN DENVER

Current Concepts in Dermatology

Meeting & Expo

September 21–25 2022

The Westin Denver Downtown Denver, CO

AOCP joins AOCD!

Pathologists learning with Dermatologist

Let AOCD track your CME
Summer is in full swing. Everyone is busy with family vacations, kids’ ballgames and summer school. It is easy to get caught up in all of these activities. The AOCD encourages all members to stay up to date with what’s going on with your organization. Keep us on your radar during these busy times.
The toughest challenges. The most advanced science.

We fight the toughest health challenges with advanced science, putting our passion to work where the need is greatest. Because our purpose as a global biopharmaceutical company is to make a remarkable impact on people’s lives.

It takes all of us to turn possibilities into medicine that reaches millions. So we partner with governments, academic institutions, scientific and advocacy groups to make it happen. Together, we’re inventing the future of medicine.

Learn more at abbvie.com

See you in Denver
Be safe when you're online

- Always verify the sender’s email address
- Never just trust the senders name or preview content
- Never open email from unknown senders
- Never, Never open attachments from unknown senders
- You can’t always trust your service provider to be secure
- 97% of all data breeches are caused by local users not paying attention to their incoming emails
American Osteopathic College of Dermatology

is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians through March 31, 2026

Graham McMahon, MD, MMSc
3/31/2022
Decision Date
DIAMOND SPONSOR

See you in Denver

TEAM AOCD
AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY
3 CONVENIENT WAYS TO CONTACT THE AOCd

by phone to 660-665-2184, Monday through Friday, 8:00 am to 4:00 pm Central Standard time

by email, dermatology@aocd.org 24/7. Staff will respond within 24 hours

by text message to 660-627-8845 24/7. Staff will respond within 24 hours
See you in Denver
Interested in becoming a D.O. speaker? D.O. dermatology speakers are lately becoming hard to find, and we need to build our numbers back up. If you are interested in joining our D.O. speaking team. Contact Marsha & Shelley at the national office.
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib. Deucravacitinib was well tolerated with a low rate of discontinuation due to adverse events (AEs).

This press release features multimedia. View the full release here:


See you in Denver!
Hello everyone,

It’s difficult to believe half of the year has passed already. It seems like we just returned from the Spring Meeting, but here we are with summer in full swing. I hope your summer season is off to a great start.

**2022 AOCD Fall Meeting**

We can’t wait to be back with you again live and in person this fall in Denver. We’re working on a great program for you with many returning speakers, and a few joining us for the first time, bringing you the latest updates on a wide variety of dermatologic topics. We anticipate offering 26 hours of CME for the conference, with lectures ranging from Mohs to skin of color to autoimmune disease and melasma. We hope you will consider joining us for what is sure to be a great opportunity to learn and gather with colleagues. [Click here to register or learn more about the 2022 AOCD Fall Meeting.](#) [Click here to reserve a room at the host hotel, the Westin Denver Downtown, at the AOCD group rate.](#)

**AOCD Super Summer On-Demand CME Package**

If you couldn’t make it to Orlando for the Spring Meeting and won’t be able to join us for the upcoming Fall Meeting but still need CME, you’re in luck! The AOCD’s Super Summer CME Package is available on AOCD Online Learning for a limited time. For those who couldn’t attend the Spring Meeting, this on-demand package is a great opportunity to take in many of the lectures presented there. Up to 12 AOA Category 1-AJAMA PRA Category 1 Credits™ are available in this package.

Pricing for this package is as follows:
- Fellow/Associate Member: $500
- Life Member: $250
- Resident & Student Member: $50
- Non-Member: $700

Please be sure to sign in to get your member rate. The correct member rate will display during the checkout process when signed in.

Before purchasing and for those who have purchased the package, please note the final date to view lecture videos in this package is **July 15, 2022**. After this date, the lectures will not be accessible.

[Click here for additional information and purchasing instructions for this package.](#)

**Resident & Student Award Opportunities**

I would like to remind and encourage all resident and student members to consider submitting an entry for the competitions currently open to them: Resident members of the AOCD are eligible to take part in the American Osteopathic College of Dermatology/Foundation for Osteopathic Dermatology Roger C. Byrd, DO, FAOCD, FAAD Clinical Manuscript Competition. Student members are invited to participate in the 1st Annual Foundation for Osteopathic Dermatology Ulbrich Circle Student Clinical Manuscript Competition.

These awards seek to recognize the entrants’ manuscripts which are judged as the best in the competition for originality, degree of scientific contribution and thoughtfulness of presentation. The deadline for entry in both competitions is September 1, 2022.

[Click here for complete details on the AOCD/FOD Roger C. Byrd, DO, FAOCD, FAAD Resident Clinical Manuscript Competition.](#)  
[Click here for complete details on the FOD Ulbrich Circle Student Clinical Manuscript Competition.](#)
CONGRATULATIONS

2022 Dermatology Graduates!

Paloma Reiter Ayala, DO; Stefanie Cabelli, DO & Gerard Danosos, DO
St. John’s Episcopal Hospital
Director: Suzanne Siota Rozenberg, DO (also pictured)

Kristian Balle, DO
Samaritan Health Services - Corvallis/Silver Falls
Dir: John Young, MD

Katrina Hansen, DO & Katherine McClure, DO
Beaumont Hospital - Farmington Hills
Director: Annette LaCasse, DO

Kristina Lim, DO & Shane Swink, DO
Lehigh Valley Health Network
Director: Cynthia Bartus, MD

Ranya Garlapati, MD; Jennifer Wong, DO; Alecia Folkes, DO & Aldhil Gupta, DO
Larkin Community Hospital - South Miami
Director: Stanley Skopit, DO

Chelsea Harper, DO & Muneeb Shah, DO
Campbell University at Sampson Regional Medical Center
Director: Jonathan Crane, DO

Joseph Aleshaki, DO; Hope Barone, DO; Morgan McNeil, DO & Emily Davis, DO
St. Joseph Mercy Hospital Livingston
Director: Daniel Stewart, DO

Ali Marzoog, MD
KCU GMEC/Phoenix
Dir: Andrew Racette, DO

Ashley Kessler, DO & Heather Ivy, DO
PCOM/Goodman Dermatology
Director: Marcus Goodman, DO (also pictured)
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of novel medicines.

With a foundation in immunology and a legacy in JAK inhibition, we are working to address significant unmet needs with products for immune-mediated skin conditions.

As a company deeply committed to the dermatology community, Incyte continues to relentlessly pursue scientific advancements to improve the lives of patients. We are excited about our dermatology portfolio and look forward to collaborating with you to make a transformative impact on the treatment of skin diseases.

Join in the excitement about our FDA-approved treatment for mild to moderate atopic dermatitis. To learn more, visit ADtreatment.com.
Hello! I hope everyone’s summer is going well.

CE Tracker is where you can find your AOCD meeting certificates. When you log-in, you need to make sure the account name is AOCDCME. Your username is the email you signed up with, and your password is ChangeMe, if you haven’t changed it yet. You can print off your certificates from there. Several have sent me other meeting certificates to enter into CE Tracker, I will be entering them soon.

We have begun a new CME cycle. Make sure you know what is required for you to maintain your board certification.

<table>
<thead>
<tr>
<th>Specialty Board</th>
<th>Total CME Requirement</th>
<th>Category 1A and/or 1B Requirements</th>
<th>Specialty-specific CME Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatology (AOBD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time-limited diplomates or non-time-limited diplomates voluntarily participating in OCC</td>
<td>60 credits of CME</td>
<td>20 credits MUST BE AOA CATEGORY 1-A CME</td>
<td>20 CREDITS MUST BE SPECIALTY SPECIFIC</td>
</tr>
<tr>
<td>Dermatology (AOBD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-time-limited diplomates not participating in OCC</td>
<td>120 credits of CME</td>
<td>20 credits MUST BE AOA CATEGORY 1-A CME</td>
<td>20 CREDITS MUST BE SPECIALTY SPECIFIC</td>
</tr>
</tbody>
</table>

For more information, please go to the following website: [https://osteopathic.org/cme/cme-guide/] or [https://certification.osteopathic.org/dermatology/] for more information regarding CME requirements and OCC requirements.

The AOCD received a 100% on our AOA document survey for re-accreditation with commendations.

Shelley Wood
Education Coordinator
Cosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditions

Basel, June 27, 2022 —

Novartis today announced the European Commission (EC) has approved Cosentyx® (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy1.

- Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA)
- Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
- Since its initial approval in 2015, Cosentyx has a proven sustained efficacy profile across several systemic inflammatory conditions and has been used to treat more than 700,000 patients worldwide1–11
From the desk of:

John Wise
Director of Events &
Information Technology

The Denver meeting will be here before you know it. We have worked hard to get things ready for our September 21st to 25th meeting. It will be a little longer stay but we have set up shorter days with our product theaters starting each morning at 8:00 am and the days ending at 5:00 pm with happy hours Thursday, Friday, & Saturday then the evening is yours. With a short walk is shopping and countless dining options. Everything from burgers and pizza to sea food and steaks at five star restaurants. You can shop till you drop on the 16th Street Mall. Free transportation up and down the street. Unlike some of our meetings you won’t be stuck on property, there is lots to do. The Denver Convention & Visitors Bureau has set up a site just for us. Visit: https://www.denver.org/welcome/aocd/.

To continue the fun this year at this meeting we will use our meeting app to add SCAN & WIN! This new feature allows attendees to scan their badge at participating vendors for the chance to win prizes. AOCD will be presenting gift cards to those lucky winners daily and a grand prize at the end of the event. PLEASE, visit EXPO CENTRAL and PLEASE visit our sponsors and vendors! Because of their annual support we are able to keep meeting and membership cost down. This year support has been at record levels, but that will only continue if you show your support for them.
We want to hear about your success with Taltz. Call 1-800-545-5979 to share your #ONTOSuccess story.

Taltz is a medication for adults and children with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

See you in Denver
SAVE the DATE

WESTIN DOWNTOWN
DENVER, CO
September 21-25
2022

HILTON WEST PALM
BEACH, FL
February 22-26
2023

WESTIN KIERLAND
SCOTTSDALE, AZ
April 10-14
2024

HILTON WEST PALM
BEACH, FL
February 19-23
2025
Office Update

Normal office hours. Monday - Friday 8:00 am till 4:00 pm cst.

We have updated our office computer system. All laptops and desktops are networked together with our servers and keep current updates. Our cell phones are integrated into our computers and phone system. We can always be reached, and will get back to you as soon as possible.

Note our phone system uses an auto attendant so you can move directly to the person you request.

As always, you can reach us by email here:

Marsha Wise - Executive Director  mwise@aocd.org
John Grogan - Member services  grogan@aocd.org
Shelley Wood - Education / CME  swood@aocd.org
John Wise - Events / Vendor  jwise@aocd.org

Contact US
AOCD
PO Box 7525
Kirksville, MO 63501
660-627-2623 (fax)

dermatology@aocd.org

Visit us on the web at www.aocd.org